{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:06:40Z","timestamp":1790255200116,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA280566"],"award-info":[{"award-number":["R21CA280566"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA292224"],"award-info":[{"award-number":["R21CA292224"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA254035"],"award-info":[{"award-number":["R01CA254035"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001081","name":"Hunter Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201307","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:12:02Z","timestamp":1784934722000},"page":"201307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["ICAM1-targeted costimulation extends HER2 CAR T cytotoxicity to HER2-low and HER2-negative tumors through synergy with TCR signaling"],"prefix":"10.1016","volume":"34","author":[{"given":"Yogindra","family":"Vedvyas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroshi","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Shin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nate R.","family":"Fredette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"de Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7748-2064","authenticated-orcid":false,"given":"Daniel J.","family":"Kota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-5796","authenticated-orcid":false,"given":"Moonsoo M.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201307_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"10.1016\/j.omton.2026.201307_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/cancers16010023","article-title":"Systemic Therapies for HER2-Positive Advanced Breast Cancer","volume":"16","author":"Angelis","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201307_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104624","article-title":"Challenges and prospects in HER2-positive breast cancer-targeted therapy","volume":"207","author":"Li","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.omton.2026.201307_bib4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201307_bib5","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201307_bib6","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201307_bib7","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201307_bib8","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201307_bib9","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2026.201307_bib10","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.omton.2026.201307_bib11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2026.201307_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201307_bib13","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/cancers15041130","article-title":"Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges","volume":"15","author":"Guidi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201307_bib14","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201307_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201307_bib16","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201307_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90064","article-title":"Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors","volume":"1","author":"Vedvyas","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2026.201307_bib18","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1158\/1078-0432.CCR-17-2008","article-title":"CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors","volume":"23","author":"Min","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201307_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4049\/jimmunol.137.1.245","article-title":"Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1)","volume":"137","author":"Dustin","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201307_bib20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.omto.2020.08.009","article-title":"Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer","volume":"18","author":"Jung","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201307_bib21","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2326-6066.CIR-21-0062","article-title":"Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses","volume":"9","author":"Yang","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201307_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.573823","article-title":"Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer","volume":"11","author":"Wei","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201307_bib23","doi-asserted-by":"crossref","first-page":"14710","DOI":"10.1073\/pnas.1408556111","article-title":"ICAM-1 as a molecular target for triple negative breast cancer","volume":"111","author":"Guo","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201307_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq7866","article-title":"A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo","volume":"9","author":"Guo","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omton.2026.201307_bib25","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-25-0529","article-title":"An ICAM1-targeting chimeric costimulatory receptor mimics the immune synapse and enhances tumor-specific T cell function","volume":"14","author":"Min","year":"2026","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201307_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.omton.2026.201307_bib27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201307_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba7308","article-title":"A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201307_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-022-01244-0","article-title":"Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells","volume":"15","author":"Tan","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201307_bib30","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/onci.19855","article-title":"OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.omton.2026.201307_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s40364-024-00684-9","article-title":"Pathophysiology and preclinical relevance of experimental graft-versus-host disease in humanized mice","volume":"12","author":"Ehx","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.omton.2026.201307_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/jhep.2002.30363","article-title":"Oligoclonal expansion of T cell receptor V beta 2 and 3 cells in the livers of mice with graft-versus-host disease","volume":"35","author":"Chen","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.omton.2026.201307_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-46938-7","article-title":"Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy","volume":"9","author":"Vedvyas","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201307_bib34","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201307_bib35","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201307_bib36","first-page":"1","article-title":"The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art","volume":"2014","author":"Montori","year":"2014","journal-title":"Int. J. Surg. Oncol."},{"key":"10.1016\/j.omton.2026.201307_bib37","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.3748\/wjg.v22.i33.7478","article-title":"Regional but fatal: Intraperitoneal metastasis in gastric cancer","volume":"22","author":"Wei","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omton.2026.201307_bib38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201307_bib39","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s43018-024-00744-x","article-title":"Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies","volume":"5","author":"Dobrin","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2026.201307_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124440","article-title":"Side-by-Side Comparison of Commonly Used Biomolecules That Differ in Size and Affinity on Tumor Uptake and Internalization","volume":"10","author":"Leelawattanachai","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201307_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2172-9-50","article-title":"Primer sets for cloning the human repertoire of T cell Receptor Variable regions","volume":"9","author":"Boria","year":"2008","journal-title":"BMC Immunol."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:40:30Z","timestamp":1790253630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001839"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201307","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ICAM1-targeted costimulation extends HER2 CAR T cytotoxicity to HER2-low and HER2-negative tumors through synergy with TCR signaling","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201307"}}